Qureight
Qureight is an AI-powered imaging CRO that provides proprietary deep-learning CT biomarkers, central imaging services and synthetic control arms to global biopharma sponsors running lung and heart disease clinical trials.
- Company typePrivate
- Founded2018
- HeadquartersCambridge, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Qureight does
Qureight is a Cambridge-headquartered AI-powered imaging contract research organization (CRO) that delivers deep-learning quantitative imaging biomarkers and trial-operations services to global biopharma sponsors developing therapies for lung and heart disease. Its proprietary platform processes standard-of-care inspiratory CT and CTPA scans through a suite of 3D volumetric convolutional neural networks branded as Fibr8 (fibrosis), Glass8 (inflammation), Air8 (airways), Vascul8 (pulmonary vasculature) and Lung8 (whole-lung and lobar volumes), each registered as a UK trademark and validated in peer-reviewed publications with a 98.4% successful CT analysis rate. The company also licenses what it describes as some of the largest real-world clinical and imaging datasets in idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, pulmonary hypertension and bronchiectasis, built through NHS and global data contracts and supplemented by OSIC membership, to support synthetic control arms, cohort enrichment, exploratory partnerships and enrolled-cohort reporting.
The offering is organised into three product lines: global imaging CRO services (image management, central reads, site onboarding, trial read-outs), AI-powered endpoints and analytics (the biomarker suite plus real-time enrolment analytics), and data science products (synthetic control arms, cohort enrichment, enrolled cohort reporting, exploratory partnerships). Revenue is generated through enterprise, quote-based contracts with global pharmaceutical and biotech sponsors; pricing is not publicly disclosed. Commercial momentum is evidenced by a customer base of 17+ named biopharma sponsors — including AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, MSD, Vicore Pharma, Avalyn, Mediar, Calluna, Rein Therapeutics, Cumberland Pharmaceuticals, Insilico Medicine and Endeavor BioMedicines — across multiple Phase 2 programmes in IPF, PPF, PH, systemic sclerosis and bronchiectasis. The company is privately held, employs ~45 people across Cambridge and London, is certified to ISO 13485:2016, ISO 27001:2022, GxP and 21 CFR Part 11, and has raised approximately £8M ($11.16M) of venture funding across seed (2022), an early round (2021) and Series A (April 2024).
Qureight firmographics
Firmographics- Name
- Qureight
- Legal name
- Qureight Limited
- Website
- https://qureight.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Qureight is an AI-powered imaging CRO that provides proprietary deep-learning CT biomarkers, central imaging services and synthetic control arms to global biopharma sponsors running lung and heart disease clinical trials.
- Ownership category
- akta.pro rank
Qureight industry classification
Industry- Product category
- Clinical Trial Imaging Analytics
- NAICS
- Scientific Research and Development Services (5417)
- akta.pro primary industry
- AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG)
Keywords
Where Qureight is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Qureight business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Revenue model
- Imaging CRO services: End-to-end imaging CRO services for global clinical trials, including automated image management, AI analysis, central reads, and clinical trial read-outs. Recurring/contract-based revenue from biopharma sponsors across multi-year clinical trial engagements.
- AI-powered endpoints and analytics: Deep learning-based quantitative imaging models (Fibr8, Glass8, Air8, Vascul8, Lung8) provided as trial endpoints and analytics. Recurring revenue through clinical trial study contracts.
- Data science products (synthetic control arms, exploratory partnerships): Synthetic control arms, cohort enrichment, exploratory partnerships and enrolled cohort reporting using real-world data assets and quantitative imaging. Project-based and exploratory partnership revenue from biopharma.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | — | Quote-based / Not publicly disclosed |
Go-to-market motion3 records
Distribution channels2 records
Marketing channels6 records
Qureight product offering
Product offeringCore offering
Qureight is a tech-first, AI-powered imaging contract research organization (CRO) that delivers three core product lines through a proprietary data and imaging curation platform: (1) Global imaging CRO services for clinical trial image management, central reads, and site onboarding; (2) AI-powered endpoints and analytics featuring proprietary deep-learning biomarkers (Lung8, Air8, Fibr8, Glass8, Vascul8) that generate compartment-specific quantitative imaging biomarkers from standard-of-care CT scans; and (3) Data science products including synthetic control arms, cohort enrichment, and exploratory partnerships leveraging real-world datasets in IPF, PPF, PH, and Bronchiectasis. Services target global biopharma sponsors conducting clinical trials in lung and heart disease.
Product overview
Qureight is a tech-first, AI-powered imaging contract research organization (CRO) that delivers its suite of products through a proprietary data and imaging curation platform. The offering is a platform-plus-modules architecture, with three core product lines that can be provided together or stand-alone: (1) Global imaging CRO services, the operational delivery engine for clinical trials including image management, central reads, and site onboarding; (2) AI-powered endpoints and analytics, a suite of deep learning–based quantitative imaging models including the proprietary Lung8™, Air8™, Fibr8™, Glass8™ and Vascul8™ models that generate compartment-specific biomarkers from CT scans; and (3) Data science products, which leverage Qureight's large real-world datasets in IPF, PPF, PH and Bronchiectasis to offer synthetic control arms, exploratory partnerships, cohort enrichment, and enrolled cohort reporting. Together these three lines enable sponsors to manage imaging workflows, generate AI-derived endpoints, and integrate quantitative imaging with real-world clinical data to accelerate lung and heart disease clinical trials.
Differentiator
Problem solved
Functional benefit
Brands
- Lung8: AI imaging biomarker model that measures whole-lung and lobar volumes from standard-of-care inspiratory CT scans; UK registered trademark of Qureight Limited.
- Air8
- Fibr8
- Glass8
- Vascul8
- Lobe8
Products and services
- Global imaging CRO services End-to-end imaging CRO services delivered on Qureight's proprietary, high-performance platform built for speed, scalability, and reliability. Provides workflow tools to improve image handling in clinical trials, accelerating patient inclusion through infrastructure that rapidly onboards global trial sites and evaluates participants in days, not weeks. Capabilities include Radiology, Clinical Biomarkers, Data curation, Data quality control, AI image analysis, Integration, KOL advisory board, Central reads, Clinical trial read-outs, and Endpoint Discovery. Offered to global biopharma sponsors.
- AI-powered endpoints and analytics Suite of deep-learning-based quantitative imaging models that generate compartment-specific biomarkers directly from standard-of-care inspiratory CT scans. Includes the proprietary Lung8, Air8, Fibr8, Glass8, and Vascul8 models, which track treatment response, predict disease progression and long-term clinical outcomes, and report baseline disease severity. Also provides real-time enrolment analytics for monitoring disease severity distributions in clinical trial cohorts. Purpose-built for interventional clinical trials in lung and heart disease and offered to biopharma sponsors.
- Data science products Data-driven product line combining Qureight's commercial access to large real-world datasets in IPF, PPF, PH, and Bronchiectasis with advanced deep learning. Includes synthetic control arms, exploratory partnerships, cohort enrichment, and enrolled cohort reporting — enabling sponsors to design smarter trials, reduce placebo arm reliance, and accelerate confident development decisions. Offered to biopharma sponsors.
Quantifiable outcome
- 98.4% successful CT analysis rate in peer-reviewed publications
- +5 more outcomes
Companies that use Qureight
Customer profileIdeal customer profiles2 records
Qureight technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability9 records
Feature8 records
Qureight partnerships and signals
Strategic signalPartnerships
22 partnerships are on record, tiered flagship / high-tier clinical trial partnership, mid-tier clinical trial partner, mid-tier clinical trial analytics partner, mid-tier clinical development partner, flagship / multi-study partner with high-profile endorsement, mid-tier early-phase trial partner, flagship / long-term clinical development partner, flagship / multi-asset strategic partner, mid-tier data ecosystem partner, mid-tier research pilot partner, flagship / strategic tier-1 global pharma partner, minor collaboration partner and customer / enterprise biopharma.
- Mediar Therapeuticsflagship / high-tier clinical trial partnershipQureight's AI-powered quantitative imaging analytics platform and services will be used to support Mediar Therapeutics' Phase 2 EncompaSSc clinical trial of MTX-474, a first-in-class monoclonal antibody targeting fibrosis in diffuse cutaneous Systemic Sclerosis. Qureight will use its Glass8, Fibr8, Vascul8, Air8 and Lung8 models to analyse HRCT lung images at screening and 24 weeks following treatment. The randomised, double-blind, placebo-controlled study will enroll participants in a 3:2 ratio receiving MTX-474 or placebo via intravenous infusion every four weeks, with an interim analysis at 12 weeks and end-of-treatment assessment at week 24.
- Endeavor BioMedicinesmid-tier clinical trial partnerElucidation of a drug mechanism for a biotech partner: Endeavor BioMedicines conducted a randomised, double-blind, placebo-controlled Phase 2a trial of ENV-101, a novel Hedgehog pathway inhibitor in IPF, with a hypothesised vascular mechanism. Qureight applied Vascul8 to baseline and end-of-study CT scans, demonstrating a statistically significant reduction in pulmonary vascular volume over 12 weeks in the active treatment arm compared with placebo (p=0.0007). Findings presented at ATS 2025 informed progression into Phase 2b.
- Calluna Pharmamid-tier clinical trial partnerQureight's AI 3D imaging platform to support Calluna Pharma's Phase 2 AURORA study of CAL101 in Idiopathic Pulmonary Fibrosis (IPF).
- Insilico Medicinemid-tier clinical trial analytics partnerQureight analyses of Insilico Medicine's Phase IIa rentosertib data support preliminary efficacy results and future trial expansion. Also compared baseline clinical and HRCT characteristics of Insilico's ISM001_055 Phase 2a trial cohort in China with Qureight's real-world IPF datasets.
- Cumberland Pharmaceuticalsmid-tier clinical development partnerPartnership to advance innovative Idiopathic Pulmonary Fibrosis (IPF) treatment research.
- Rein Therapeuticsflagship / multi-study partner with high-profile endorsementRein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF. Rein Therapeutics and Qureight have since broadened their life science collaboration. Dr Steven Shoemaker (Rein CMO) endorsed Qureight: 'Qureight delivered our first qualified imaging site just 2-3 weeks after study contract. The science is excellent — and the people may be even better.'
- Remedy Cellmid-tier early-phase trial partnerPartnership to integrate Qureight's deep learning platform into Phase 1b study of RC-0315 in IPF.
- Vicore Pharmaflagship / long-term clinical development partnerVicore Pharma is using Qureight's AI-powered imaging platform across multiple studies of buloxibutid for IPF, including the Phase 2b ASPIRE study. Vicore has been a long-term partner, with prior collaborations including the AIR C21 study (where Qureight created a matched synthetic control arm) and Qureight is now running AI-powered analytics across multiple Vicore assets. Vicore CMO Dr Bertil Lindmark endorses Qureight as a "real powerhouse" in lung fibrosis.
- Avalyn Pharmaflagship / multi-asset strategic partnerStrategic partnership in Progressive Pulmonary Fibrosis (PPF). Qureight's deep learning platform is being used in Avalyn's ongoing MIST study to measure treatment response, quantifying changes in fibrosis volume and across multiple compartments of the lung. Qureight is now running multiple products across multiple assets within Avalyn Pharma's portfolio. Avalyn CMO Dr Howard M. Lazarus endorses Qureight's capability to measure treatment response in PPF.
- Open Source Imaging Consortium (OSIC)mid-tier data ecosystem partnerQureight joined OSIC and gained access to the world's largest, curated data repository for Interstitial Lung Diseases (ILDs), enhancing its real-world data and biomarker development capabilities.
- King Faisal Specialist Hospital and Research Centremid-tier research pilot partnerPartnership for an Innovative Lung Transplant Research Pilot, leveraging Qureight's AI imaging platform for transplant-related research at KFSH&RC in Saudi Arabia.
- AstraZenecaflagship / strategic tier-1 global pharma partnerMulti-year research collaboration on lung disease, including the PROFILE IPF dataset. Qureight ran multiple deep learning imaging models on baseline data and combined outputs with proteomic biomarkers of interest, showing that deep learning measures of fibrosis combined with protein biomarkers of epithelial injury and collagen turnover (CYFRA21-1, SPD, ProC6) predicted mortality in IPF, independently of physiological biomarkers such as FVC. AstraZeneca has also adopted Qureight's platform for IPF research.
- patientMpowerminor collaboration partnerQureight is partnering with patientMpower to reveal AI insights for improved ILD (Interstitial Lung Disease) care, combining patientMpower's digital health platform with Qureight's AI imaging models.
- Bristol-Myers Squibb (BMS)customer / enterprise biopharmaBMS appears as a customer logo on the Qureight website, indicating an enterprise customer relationship using Qureight's AI-powered imaging CRO services.
- Daiichi Sankyocustomer / enterprise biopharmaDaiichi Sankyo appears as a customer logo on the Qureight website, indicating an enterprise customer relationship using Qureight's AI-powered imaging CRO services.
- MSD (Merck Sharp & Dohme)customer / enterprise biopharmaMSD appears as a customer logo on the Qureight website, indicating an enterprise customer relationship using Qureight's AI-powered imaging CRO services.
- PureTech Healthcustomer / enterprise biopharmaPureTech Health appears as a customer logo on the Qureight website, indicating an enterprise customer relationship using Qureight's AI-powered imaging CRO services.
- Galectocustomer / enterprise biopharmaGalecto appears as a customer logo on the Qureight website, indicating an enterprise customer relationship using Qureight's AI-powered imaging CRO services.
- Contineum Therapeuticscustomer / enterprise biopharmaContineum Therapeutics appears as a customer logo on the Qureight website, indicating an enterprise customer relationship using Qureight's AI-powered imaging CRO services.
- Pulmongenecustomer / enterprise biopharmaPulmongene appears as a customer logo on the Qureight website, indicating an enterprise customer relationship using Qureight's AI-powered imaging CRO services.
- Istessocustomer / enterprise biopharmaIstesso appears as a customer logo on the Qureight website, indicating an enterprise customer relationship using Qureight's AI-powered imaging CRO services.
- CP (referenced as CPLogo on homepage)customer / enterprise biopharmaAppears as a customer logo on the Qureight website under CPLogo filename; identity refers to an enterprise biopharma partner.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
Qureight competitors and assessment
Company assessmentDirect peers
- IXICO: UK-based imaging analytics CRO that provides imaging biomarkers and central reading services for clinical trials in CNS and other indications. Directly comparable to Qureight as a technology-enabled, contract-based imaging biomarker provider serving global biopharma with proprietary AI image analysis.
- Median Technologies: French-listed imaging CRO focused on AI-driven imaging for oncology clinical trials, providing iCRO services and quantitative imaging biomarkers. Comparable to Qureight in business model (imaging CRO), customer base (global biopharma), and product offering (AI imaging biomarkers and central reads).
- Perspectum: UK-based medical imaging company that develops AI-based quantitative imaging biomarkers for clinical trials and clinical practice, primarily in metabolic disease (liver, oncology). Directly comparable in offering AI-derived quantitative imaging endpoints to global pharma sponsors for use as trial endpoints.
- Calyx (formerly Image Analysis Group): Imaging CRO offering central reading, AI-enabled image analysis, and imaging trial management for biopharma sponsors. Closely comparable to Qureight in service offering and customer base, with a stronger footprint in oncology and CNS imaging.
Broad incumbents
- Clario: Large, established imaging and eCOA CRO formed via the merger of Bioclinica and ERT. Provides central imaging reads, imaging management, and AI-augmented analysis across many therapeutic areas. Overlaps with Qureight in imaging CRO services but operates at significantly broader scale and indication coverage.
- Tempus Labs: Large AI-driven precision medicine company combining clinical, molecular, and imaging data for biopharma and providers. Overlaps with Qureight on AI-powered clinical trial analytics and real-world data assets but operates at vastly broader scope across oncology and many other indications.
- PAREXEL (or any major broad CRO with imaging arm): Top-tier global full-service CRO with imaging and central lab capabilities across Phase 1-4 trials. Competes with Qureight for end-to-end trial sponsors that bundle imaging with broader CRO services, but lacks Qureight's depth in lung-specific AI imaging biomarkers.
Emerging players
- Owkin: AI-for-clinical-research company applying machine learning to clinical and multi-omics data for biopharma sponsors, with growing synthetic/external control arm capabilities. Comparable to Qureight on the AI-driven trial analytics and data-science-product side, though it does not specialise in lung/cardiac imaging.
- Flywheel: Imaging data management and AI analytics platform for clinical research, offering data curation, automated workflows, and imaging biomarkers for sponsors. Comparable to Qureight on the data curation and AI image analysis layer of clinical trial imaging workflows.
- Arterys: Cloud-native AI imaging platform with FDA-cleared deep learning models for medical imaging analysis (originally MRI, expanding to CT). Comparable on AI imaging infrastructure and regulatory pathway, with partial overlap on CT biomarker use cases for clinical and research settings.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Qureight social profiles
Digital presenceQureight compliance and trust
Trust signalCompliance5 records
Qureight financial estimates
Financial estimateRevenue estimate
Valuation estimate
Qureight leadership team
Management profileNumber of profiles
Profiles10 records
Qureight funding detail
Funding detailFunding overview
Funding rounds4 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Qureight M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Qureight
What does Qureight do?
Qureight is a tech-first, AI-powered imaging contract research organization (CRO) that delivers three core product lines through a proprietary data and imaging curation platform: (1) Global imaging CRO services for clinical trial image management, central reads, and site onboarding; (2) AI-powered endpoints and analytics featuring proprietary deep-learning biomarkers (Lung8, Air8, Fibr8, Glass8, Vascul8) that generate compartment-specific quantitative imaging biomarkers from standard-of-care CT scans; and (3) Data science products including synthetic control arms, cohort enrichment, and exploratory partnerships leveraging real-world datasets in IPF, PPF, PH, and Bronchiectasis. Services target global biopharma sponsors conducting clinical trials in lung and heart disease.
Is Qureight a public or private company?
Qureight is a private company. It is classified as venture growth investor backed and is currently operating.
When was Qureight founded?
Qureight was founded in 2018. It employs 11 to 50 people.
Where is Qureight based?
Qureight is headquartered in Cambridge, United Kingdom, in the Europe region.
How does Qureight make money?
Three revenue lines are on record. Imaging CRO services are the primary driver. The others are AI-powered endpoints and analytics and data science products (synthetic control arms, exploratory partnerships).
Who are Qureight's main competitors?
Direct peers on record are IXICO, Median Technologies, Perspectum and Calyx (formerly Image Analysis Group). Broad incumbents are Clario, Tempus Labs and PAREXEL (or any major broad CRO with imaging arm). Emerging players are Owkin, Flywheel and Arterys.
Does Qureight have an API?
No public API is recorded for Qureight.
What industry is Qureight in?
Qureight's product category is Clinical Trial Imaging Analytics. Its primary akta.pro industry code is HLACALAG, AI Orchestration & Imaging Analytics Platforms (Model Management/Triage). Its NAICS code is 5417.